BERLIN — New data from two new studies suggest that for patients with multiple sclerosis (MS) for whom treatment with natalizumab (Tysabri, Biogen) or fingolimod (Gileyna, Novartis) fails, switching ...

Fatal adverse events (AEs) associated with alemtuzumab for multiple sclerosis (MS) may occur more frequently than previously understood based on past published literature, researchers found. Patients ...

Alemtuzumab improved clinical and magnetic resonance imagining outcomes in patients with relapsing-remitting multiple sclerosis across varying age groups and maintained efficacy through year 8 of ...

DALLAS -- Alemtuzumab (Lemtrada) continued to show benefits in clinical outcomes, lesion load, and brain volume loss in relapsing-remitting multiple sclerosis (MS) for 8 years, an extension study of ...

A drug which 'reboots' a person's immune system has been shown to be an effective treatment for multiple sclerosis (MS) patients who have already failed to respond to the first drug with which they ...

CAMMS223 Trial Investigators (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786–1801 Immunotherapy might only affect long-term disability in multiple ...

The multiple sclerosis (MS) therapy alemtuzumab can trigger severe, unpredictable side effects. This was the finding by a team led by Prof Dr Aiden Haghikia and Prof Dr Ralf Gold from the Department ...

Co announced that top-line, three-year data from a completed Phase 2 clinical trial comparing alemtuzumab with Rebif (interferon beta- 1a) for the treatment of ...

The investigators of this study sought to evaluate the long-term efficacy and safety of alemtuzumab to treat patients of African descent who have relapsing-remitting MS. SEATTLE – Alemtuzumab is ...